Top

Published in:

01-03-2009 | Original Article

VEGF-C and VEGFR-3 in a series of lymphangiomas: Is superficial lymphangioma a true lymphangioma?

Authors: Eijun Itakura, Hidetaka Yamamoto, Yoshinao Oda, Masutaka Furue, Masazumi Tsuneyoshi

Published in: Virchows Archiv | Issue 3/2009

Abstract

Lymphangiomas are commonly regarded as vascular malformations during embryonic development rather than as true neoplasms. VEGF-C and VEGFR-3 are known to be active in the formation of lymphangiomas. However, the significance of the disorders seems to be obscured by confusing different entities. In 114 lymphangiomas, we investigated the clinicopathological features and the expression of VEGF-C and VEGFR-3. The age of patients with lymphangioma circumscriptum or intraabdominal lymphangioma was significantly higher than in patients with cavernous lymphangioma and in patients with cystic hygroma. In cavernous lymphangioma, the age of female patients was significantly higher than in male patients. Five adult cystic hygromas were identified. VEGF-C was detected in 21 of 58 (36%) cavernous lymphangiomas, ten of 28 (36%) cystic hygromas, 0 of 12 (0%) lymphangioma circumscriptum, and four of ten (40%) intraabdominal lymphangiomas. VEGFR-3 was detected in 43 of 58 (72%) cavernous lymphangiomas, 20 of 28 (71%) cystic hygromas, six of 12 (50%) lymphangiomas circumscriptum, and seven of ten (70%) intraabdominal lymphangiomas. VEGF-C was absent from superficial lymphangiomas associated with cavernous lymphangiomas. In typical cases of cavernous lymphangioma, VEGF-C was strongly expressed, suggesting that these cases possessed proliferative activity. In cystic hygroma and intraabdominal lymphangioma, VEGF-C was limited in its distribution. Superficial lymphangiomas more likely represent from peripheral lymphatic dilatation rather than due to growth factor.

Takahashi K, Mulliken JB, Kozakewich HP et al (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357–2364PubMedCrossRef

Boye E, Yu Y, Paranya G et al (2001) Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 107:745–752PubMedCrossRef

Khan ZA, Melero-Martin JM, Wu X et al (2006) Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 108:915–921PubMedCrossRef

Weiss SW, Goldblum JR (2001) Enzinger and Weiss’s soft tissue tumors, 4th edn. Mosby. St. Louis, MO

Flanagan BP, Helwig EB (1977) Cutaneous lymphangioma. Arch Dermatol 113:24–30PubMedCrossRef

Diaz-Cascajo C, Borghi S, Weyers W et al (1999) Benign lymphangiomatous papules of the skin following radiotherapy: a report of five new cases and review of the literature. Histopathology 35:319–327PubMedCrossRef

Sangeza OP, Requena L (2003) Pathology of vascular skin lesions: clinicopathological correlations. Humana, Totowa, NJCrossRef

Oliver G, Alitalo K (2005) The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol 21:457–483PubMedCrossRef

Cueni LN, Detmar M (2006) New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol 126:2167–2177PubMedCrossRef

10.

Kaipainen A, Korhonen J, Mustonen T et al (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92:3566–3570PubMedCrossRef

11.

Jeltsch M, Kaipainen A, Joukov V et al (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423–1425PubMedCrossRef

12.

Stacker SA, Achen MG, Jussila L et al (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2:573–583PubMedCrossRef

13.

Huang HY, Ho CC, Huang PH et al (2001) Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Lab Invest 81:1729–1734PubMed

14.

Norgall S, Papoutsi M, Rossler J et al (2007) Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. BMC Cancer 7:105PubMedCrossRef

15.

Kasten P, Schnöink G, Bergmann A et al (2007) Similarities and differences of human and experimental mouse lymphangiomas. Dev Dyn 236:2952–2961PubMedCrossRef

16.

Saito T, Terada K, Tsuchiya K et al (1999) Lymphangioma presenting as a dumbbell tumor in the epidural space of the lumbar spine. Spine 24:74–76PubMedCrossRef

17.

Itakura E, Yamamoto H, Oda Y et al (2008) Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 97:74–81PubMedCrossRef

18.

Wilcox RR (2005) Introduction to robust estimation and hypothesis testing, 2nd edn. Elsevier, Burlington, MA

19.

Lymboussaki A, Olofsson B, Eriksson U et al (1999) Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ Res 85:992–999PubMed

20.

Mäkinen T, Veikkola T, Mustjoki S et al (2001) Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762–4773PubMedCrossRef

21.

Pytowski B, Goldman J, Persaud K et al (2005) Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 97:14–21PubMedCrossRef

22.

Dumont DJ, Jussila L, Taipale J et al (1998) Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282:946–949PubMedCrossRef

23.

Partanen TA, Alitalo K, Miettinen M (1999) Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86:2406–2412PubMedCrossRef

24.

Folpe AL, Veikkola T, Valtola R et al (2000) Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, Kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 13:180–185PubMedCrossRef

25.

Skobe M, Brown LF, Tognazzi K et al (1999) Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi’s sarcoma. J Invest Dermatol 113:1047–1053PubMedCrossRef

26.

Galambos C, Nodit L (2005) Identification of lymphatic endothelium in pediatric vascular tumors and malformations. Pediatr Dev Pathol 8:181–189PubMedCrossRef

27.

Chervenak FA, Isaacson G, Blakemore KJ et al (1983) Fetal cystic hygroma. Cause and natural history. N Engl J Med 309:822–825PubMed

28.

Ganapathy R, Guven M, Sethna F et al (2004) Natural history and outcome of prenatally diagnosed cystic hygroma. Prenat Diagn 24:965–968PubMedCrossRef

29.

Gedikbasi A, Gul A, Sargin A et al (2007) Cystic hygroma and lymphangioma: associated findings, perinatal outcome and prognostic factors in live-born infants. Arch Gynecol Obstet 276:491–498PubMedCrossRef

30.

Goodman J, McClintock J, Denton GR et al (1963) Cystic hygromas in adults. Arch Surg 86:641–644PubMed

31.

Nussbaum M, Buchwald RP (1981) Adult cystic hygroma. Am J Otolaryngol 2:159–162PubMedCrossRef

32.

Baer S, Davis J (1989) Cystic hygroma presenting in adulthood. J Laryngol Otol 103:976–977PubMedCrossRef

33.

Gleason TJ, Yuh WTC, Tali ET et al (1993) Traumatic cervical cystic lymphangioma in an adult. Ann Otol Rhinol Laryngol 102:564–566PubMed

34.

Morley SE, Ramesar KCRB, Macleod DAD (1999) Cystic hygroma in an adult: a case report. J R Coll Surg Edinb 44:57–58PubMed

35.

Leipzig B, Rabuzzi DD (1978) Recurrent massive cystic lymphangioma. Otolaryngology 86:758–760

36.

Scally CM, Black JH (1990) Cystic hygroma: massive recurrence in adult life. J Laryngol Otol 104:908–910PubMedCrossRef

37.

Peachey RD, Lim CC, Whimster IW (1970) Lymphangioma of skin. A review of 65 cases. Br J Dermatol 83:519–527PubMedCrossRef

38.

Russell B, Pridie RB (1967) Lymphangioma circumscriptum with involvement of deep lymphatics. Br J Dermatol 79:300

39.

Mahle C, Schwartz M, Popek E et al (1997) Intra-abdominal lymphangiomas in children and adults. Assessment of proliferative activity. Arch Pathol Lab Med 121:1055–1062PubMed

40.

Brown M, Pysher T, Coffin CM (1999) Lymphangioma and congenital pulmonary lymphangiectasis: a histologic, immunohistochemical, and clinicopathologic comparison. Mod Pathol 12:569–575PubMed

Title: VEGF-C and VEGFR-3 in a series of lymphangiomas: Is superficial lymphangioma a true lymphangioma?
Authors: Eijun Itakura
Hidetaka Yamamoto
Yoshinao Oda
Masutaka Furue
Masazumi Tsuneyoshi
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 3/2009
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-008-0720-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

VEGF-C and VEGFR-3 in a series of lymphangiomas: Is superficial lymphangioma a true lymphangioma?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism

Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol)

Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis

Dendritic cell sarcomas/tumours of the breast: report of two cases

Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH)

The Salafia method rediscovered